Chongqing Pharscin Pharmaceutical (SHE:002907) received the approval of the drug administration of China's Chongqing Municipality to re-register an active pharmaceutical ingredient, or API, and a drug, according to a Shenzhen Stock Exchange filing on Wednesday.
The approval is for the API used to produce aluminum carbonate tablets, hydrotalcite, and the drug for ischemic cerebrovascular diseases, troxerutin injection.
The approval for both products are valid until Sept. 29, 2029, the pharmaceutical company said.
Price (RMB): ¥13.28, Change: ¥-0.050, Percent Change: -0.38%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments